Ok, I guess you'd need Rs. 850,000 to begin with.
Sitara Peroxide (SPL) has yielded a 17.5% return since I published my recommendation
six days ago. So if anyone had invested Rs. 851,000 in the stock at the time I published my recommendation, he'd indeed be a millionaire right now :P. The return is even more enticing given that the KSE 100 index has lost more than 5% of its value during the period. This means that the recommendations have acually beaten the market by around 22.5% during the six days ending today.
The story of Descon Oxychem (DOL), SPL's spiritual sister (spiritual since it has the same driving factors as SPL) is no different as it has yielded a similar return of 17.3% during the period.
The basis for the recommendation was simple. Increased peroxide prices would (the companies' product) result in increased gross margins. A constant cost base was also highlighted, as government changes gas prices only on a six monthly basis and the last change would not take place untill for the Septmebr quarter.
Moreover, as borrowed from a daily of SC securities, and credit duly given, decreasing finance costs in view of improved cash flows would further boost earnings.
Both the recommendations were correct and as it turned out, gross margin did increase for both the stocks and the finance costs decreased as well. Moreover, the EPS of especially DOL incerased significantly and the company recorded its highest EPS in 6 quarters.
The EPS chart along with the updated gross margin chart, which is the cornerstone of this analysis is presented below for illustration:
So whats next? My initial thesis was better still results for the September quarter due to even higher peroxide prices. The low finance costs theme should follow through as well driven by further improvement in cash flows. Gas price increase should have posed a risk for the stock since its the major raw material, but that risk has been nullified given the government's decision to deferr the same till November.
Any production and sales hiccups could however disrupt revenues and earnings potential, however if this serves as any consolation, sales and revenues have been relatively stable for the two companies given the historical trend.
Hence in view of further rise in peroxide prices, together with a calculated assumption of constant production and sales, I would still stick to my assertion of further improvement in financial performance for both the stocks for the quarter ended September 30th, 2013.
Sitara Peroxide (SPL) has yielded a 17.5% return since I published my recommendation
six days ago. So if anyone had invested Rs. 851,000 in the stock at the time I published my recommendation, he'd indeed be a millionaire right now :P. The return is even more enticing given that the KSE 100 index has lost more than 5% of its value during the period. This means that the recommendations have acually beaten the market by around 22.5% during the six days ending today.
The story of Descon Oxychem (DOL), SPL's spiritual sister (spiritual since it has the same driving factors as SPL) is no different as it has yielded a similar return of 17.3% during the period.
The basis for the recommendation was simple. Increased peroxide prices would (the companies' product) result in increased gross margins. A constant cost base was also highlighted, as government changes gas prices only on a six monthly basis and the last change would not take place untill for the Septmebr quarter.
Moreover, as borrowed from a daily of SC securities, and credit duly given, decreasing finance costs in view of improved cash flows would further boost earnings.
Both the recommendations were correct and as it turned out, gross margin did increase for both the stocks and the finance costs decreased as well. Moreover, the EPS of especially DOL incerased significantly and the company recorded its highest EPS in 6 quarters.
The EPS chart along with the updated gross margin chart, which is the cornerstone of this analysis is presented below for illustration:
Any production and sales hiccups could however disrupt revenues and earnings potential, however if this serves as any consolation, sales and revenues have been relatively stable for the two companies given the historical trend.
Hence in view of further rise in peroxide prices, together with a calculated assumption of constant production and sales, I would still stick to my assertion of further improvement in financial performance for both the stocks for the quarter ended September 30th, 2013.
No comments:
Post a Comment